NOV 15, 2018 04:00 AM PST

Generation and application of 3D-organoid cell culture models using human induced pluripotent stem cells (iPSCs) for drug discovery

Speakers
  • Associate Director - Stem & Primary Cell Group, AstraZeneca
    Biography
      Ryan Hicks is the Associate Director of the Stem & Primary Cell Group at AstraZeneca. Ryan's group is responsible for the generation, engineering and differentiation of iPS cells, adult stem cells and use of primary cells for assay development, target validation, hit finding, hit-to-lead, lead optimization and phenotypic screening activities. Models are generated in 2D and 3D cultures and part of the model development work includes using precise genome modification techniques to introduce gene knock-outs, knock-in mutations or endogenous reporters into iPS cells. The groups work primarily focuses on AstraZeneca's cardiovascular, metabolic, renal and respiratory disease areas. Ryan Hicks joined AstraZeneca in 2001 and has been based in Sweden for the past 8 years. Prior to working in Sweden, Ryan worked as the Associate Director of the Cell & Protein reagents group at AstraZeneca, Alderley Park, UK, with responsibilities in the cell and protein disciplines. Ryan Hicks received his degree in Medical Biochemistry from the University of Birmingham, UK. Following this Ryan received his Ph.D. in Biochemistry and Molecular Biology from the University of Leeds, UK, in 2001.

    Abstract:

    Development of physiologically relevant cellular models, with strong translatability to human pathophysiology, is critical for identification and validation of novel therapeutic targets. Cell types derived from induced pluripotent stem cells (iPSCs) provide an important resource for modelling native biology in human cells and tissues for drug discovery.  Understanding the phenotypic and functional relevance of these iPSC derived cells and tissues and how well they represent human biology is vital and as such we have developed tool iPSC-lines and techniques to optimize and monitor differentiation. Applying CRISPR/Cas9, Next Generation Sequencing (NGS), functional testing and advanced imaging techniques to iPSC model validation, we have established a platform that enables an accurate assessment of their benefits, maturity, gaps and challenges, as well as application in a drug discovery setting. Data presented will be from a key kidney model system we have developed to examplify our platforms.  This will describe the validation and application of our kidney model, using SIX2 and NPHS1 markers non-invasively in real-time, to trace early nephron commitment and podocyte-maturation in the same cell. In adition, we will also describe how we use transcriptomic analysis by NGS, in addition to functional assays, to get the most from our iPS derived 3D cell models.


    Show Resources
    You May Also Like
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    MAR 20, 2019 09:00 AM PDT
    C.E. CREDITS
    MAR 20, 2019 09:00 AM PDT
    DATE:  March 20, 2019TIME:  9:00am PDT...
    Loading Comments...
    Show Resources